CULLINAN THERAPEUTICS INC
CGEMNASDAQTrading Snapshot
- Day Range
- $15.04 – $15.44
- 52-Week Range
- $5.68 – $23.19
- Volume
- $3.68B
- Avg Volume
- $2.77B
- Shares Outstanding
- 61.5M
- Next Earnings
- Oct 30, 2026
Fundamentals Snapshot
- Annual Revenue
- $65M
- Last Q Revenue
- $17M
- P/E Ratio
- -4.4
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-3.33
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1.1%
Why Investors Own CGEM
- ✓High-growth profile — revenue up +53.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 46% gross margin and 15% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CULLINAN THERAPEUTICS INC
CGEM
StockOtter · stockotter.spaceAbout CULLINAN THERAPEUTICS INC
Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune Diseases
I think Cullinan Therapeutics' recent pullback is a compelling price entry ahead of their clinical updates. CGEM has scheduled updates for its autoimmune pipeline for December 2026. The combined CLN-978 results could hel
Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049
Cullinan Therapeutics NASDAQ: CGEM outlined upcoming clinical milestones across its immunology and oncology pipeline, including a planned December update for its CD19-directed T-cell engager CLN-978 and data presentation
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and Sjögren's disease in December CLN-049 (FLT3 TCE) updated data from the
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
CAMBRIDGE, Mass., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T
Engineers Gate Manager LP Increases Stock Position in Cullinan Therapeutics, Inc. $CGEM
Engineers Gate Manager LP raised its stake in shares of Cullinan Therapeutics, Inc. (NASDAQ: CGEM) by 130.9% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchan
Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call Transcript
Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call Transcript